The folate antagonist methotrexate is a cytotoxic drug used in the treatment of several cancer types. The entry of methotrexate into the cell is mediated by two main transport systems: the reduced folate carrier and membraneassociated folate receptors. These transporters differ considerably in their mechanism of (anti)folate uptake, substrate specificity, and tissue specificity. Although the mechanism of action of the reduced folate carrier is fairly well-established, that of the folate receptor has remained unknown. The development of specific folate receptor-targeted antifolates would be accelerated if additional mechanistic data were to become available. In this work, we used two fluorescently labeled conjugates of methotrexate, differently linked at the terminal groups, to clarify the uptake mechanism by folate receptor-α. The results demonstrate the importance of methotrexate amino groups in the interaction with folate receptor-α.
T he folate antagonist methotrexate (MTX) was introduced into oncology as a cytotoxic antiproliferative agent that has been used in the treatment of various cancer types for decades. 1 It is an antimetabolite that inhibits dihydrofolate reductase (DHFR), which is an enzyme involved in the biosynthetic pathway of nucleotides, and MTX is therefore highly toxic to rapidly dividing cancer cells. 2 The first pivotal step in the cellular pharmacology of MTX is its entry into the cell, which can be mediated by two general transport systems: the reduced folate carrier (RFC) and membrane-associated folate receptors (FRs). These transport routes are physiologically and pharmacologically relevant for immunocompetent cells because they facilitate the uptake of natural reduced folate cofactors and folate antagonists, such as MTX. 3 The RFC and FRs differ considerably in their mechanism of (anti)folate uptake (transmembrane carrier vs endocytosis), substrate specificity (low-affinity folic acid/highaffinity MTX vs high-affinity folic acid/low-affinity MTX), and tissue specificity (constitutive vs restricted expression) ( Figure 1 ).
The membrane-spanning anion transporter RFC has a constitutive expression in essentially all human tissues, providing a high-affinity bidirectional exchange mechanism for reduced folate cofactors and MTX (K m = 1−10 μM). Inversely, the RFC binding affinity for folic acid is low (K i = 200−400 μM). 4, 5 A second folate transport mechanism is mediated by FR, a particulate form of folate binding proteins, which are anchored to the cell membrane by glycosylphosphatidylinositol (GPI) residues. FRs have a mass of 38−40 kDa and are encoded by two genes (FR α and β) with differential tissue expression. The α-isoform of FR is overexpressed in specific types of cancer (e.g., ovarian cancer), 6 while the β isoform on activated macrophages. 7 The third member of this gene family, γ-type, is a secretory protein, from hematopoietic cells, because of the lack of a signal for GPI attachment. 8 Unlike RFC, FR exhibits a much greater affinity for folic acid and 5-methyltetrahydrofolate (K d = 1−10 nM) but lower for other reduced folates and MTX (K d = 10−300 nM). FRs also have different properties in terms of energy, ion, and pH dependence. 4 The level of binding of folate to FR is decreased after energy depletion and in the absence of chloride anion but does not decrease until the pH falls below 5.0. 9 The functional activity of the RFC-mediated cellular traffic of antifolates with antitumor activity in vivo is fairly wellestablished. 5 On the contrary, the exact role and mechanism of action of the FRα have remained unclear. 10 In 2013, the structure−activity relationship for molecular (high-affinity) recognition of folate and folate conjugates by FRα was disclosed. 11 It was demonstrated that FRα has a globular structure stabilized by eight disulfide bonds and contains a folate binding pocket formed of conserved residues (across all receptor subtypes). 11 The molecular model reveals that the glutamate moiety is solventexposed and projects from the receptor's pocket entrance, enabling cargo attachment without obstructing FRα binding. 11 This structure helps explain the low binding affinity of MTX for FRα, because it shows that there is a steric impediment of a specific amino group that interferes with the binding to the receptor.
Knowing the molecular recognition details and considering that MTX is transported into cells via the FR rather than through facilitative transporters (expressed in normal tissues), one could not expect damage to normal cells. 12 Therefore, FRα-targeted therapy should focus on overcoming the affinity and specificity for MTX, over RFC. This could be achieved through engineering of molecules that take advantage of the many solvent-filled cavities that surround ligands in the folate receptor binding cleft. 12 In the study presented here, we elucidate the mechanism of uptake of MTX by FRα. Two fluorescently labeled conjugates of MTX, differently linked at the terminal groups, were used for cellular uptake, and molecular docking and molecular dynamics simulations were performed to validate their findings.
■ METHODS Fluorescent Labeling of MTX. MTX was labeled with the amino-reactive fluorescent dye Red Mega 520 NHS-ester (fluorescent red), as previously described for folic acid. 13 Briefly, 140 μL of an MTX solution [3.7 mg/mL in a 3:1 mixture of 50 mM bicarbonate buffer (pH 9) and dimethylformamide (DMF)] was mixed with 28 μL of a fluorescent red solution (20 mg/mL in DMF), and 200 μL of DMF was added. The mixture was shaken for 4 h at 25°C under light protection. The product was purified by size exclusion chromatography using a HiTrap Desalting column (GE Healthcare Europe GmbH, Vienna, Austria) installed on an Äkta Purifier system (Amersham Pharmacia Biotech, Uppsala, Sweden) with 50 mM potassium phosphate and 100 mM NaCl (pH 7) as the eluent, at the flow rate of 1 mL/min, to remove excess fluorescent red. Fractions, which showed absorbance at 520 nm for fluorescent red and 368 nm for MTX, were collected. Electrospray ionization (ESI) was performed in a Thermo FR Confirmation by Real-Time Quantitative Polymerase Chain Reaction (qPCR). Cell lysates of different-origin cancer lines were collected, and total RNA was extracted using the "SV Total RNA Isolation System", according to the manufacturer's protocol (Promega Corp.). Following column elution with 30 μL of RNase-free water, the RNA concentration was determined by measuring the absorbance at 260 nm in a NanoDrop ND-1000 spectrophotometer (A 260 = 1−40 μg/mL) (Nanodrop Technologies). The A 260 /A 280 ratio was calculated to estimate RNA purity. Reverse transcription was performed using the "iScriptTM cDNA synthesis kit" (Bio-Rad Laboratories). Unique blended oligo(dT) and random hexamer primers were incubated according to the manufacturer's protocol as follows: 5 min at 25°C, 60 min at 42°C, 5 min at 85°C, and hold at 4°C. For confirmation of FRα and RFC expression levels, TaqMan probe-based gene expression assays (Applied Biosystems, Spain) were considered: Hs01124177_m1 and Hs00953345_m1, respectively. Real-time qPCRs were performed in a CFX96 Real-Time PCR Detection System, with a C1000TM thermal cycler (Bio-Rad Laboratories). The amplification process used the following conditions: UNG incubation at 50°C for 2 min, polymerase activation at 95°C for 10 min, denaturation at 95°C for 15 s, and annealing/extension at 60°C for 60 s, for 50 cycles (data collection). A stable endogenous control gene, cyclin-dependent kinase inhibitor 1A, CDKN1A (TaqMan assay Hs00355782_m1; Applied Biosystems, Spain), was used for normalization of the expression values.
Uptake Experiments. The FRα-positive cells (KB cancer cell line) and MDA-MB-435S cells (negative control) were harvested from the culture vessel during their S-phase (i.e., until a monolayer, with a confluence of >60%, was obtained) and seeded at a density of 100000 cells/mL (24-well microplates) for the uptake experiments. After an overnight period to ensure optimal adhesion, the culture medium was removed, and adherent cells were washed twice with acidic phosphatebuffered saline (pH 3.5) to remove bound folic acid. The MTX conjugates were diluted in Hanks' balanced salt solution (folate-free) at a nontoxic (data not shown) concentration of 6 μM (adjusted for antifolate concentration) and incubated in cancer cells for 4 h. The same experiment was repeated using medium containing 113 μM free folic acid (Sigma) and calcium folinate (TCI) to determine the effect of FR and RFC blockade, respectively. The cultures were maintained under a humidified atmosphere containing 5% CO 2 in a 37°C incubator. The internalized concentration of MTX conjugates was determined, considering the fluorescence intensity measured (PerkinElmer LS-50B luminescence spectrometer) upon lysis of the exposed cells. All values were corrected by the intensity/molarity ratio, according to calibration curves of fluorescently labeled conjugates.
Molecular Docking Simulations. The computational models of FRα, RFC, and MTX have different origins. The FRα model corresponds to entry 4KM6 of the RCSB Protein Data Bank (PDB), 14 that is an X-ray diffraction of human FRα (FOLR1) at acidic pH. The software Modeler (https://salilab. org/modeller) 15 was used to obtain a three-dimensional model of RFC protein, through homology with a structure of a transmembrane glucose transporter obtained by X-ray diffraction (PDB entry 4ZW9), 16 due to the lack of a full crystallographic model of RFC. Finally, the MTX structure was obtained using the "Automated Topology Builder (ATB) and Repository" online server (https://atb.uq.edu.au/) 17 using AM1-optimized geometry and MOPAC charges.
The models of FRα, RFC, and MTX were preprocessed with Autodock tools 18 to correct the charges, the hydrogens, and the bond flexibility when needed. Later, Autodock Vina 19 was used to perform the docking simulations between FRα and MTX and between RFC and MTX to evaluate the binding affinity between them. All docking calculations were performed with one 5 nm × 5 nm × 5 nm box centered on the FR active site, and the exhaustiveness was varied between 80 and 800.
Molecular Dynamics Simulations. The simulations were performed with the GROMACS 4.6.5 20 package using the GROMOS 54A7 force field. 21, 22 The initial configurations of the protein−MTX conjugates were the result of docking simulations with higher binding energies. These structures were solvated and simulated for a few nanoseconds (∼10 ns).
The bond lengths of the proteins were constrained with LINCS, 23 and those for water with SETTLE. 24 Nonbonded interactions were calculated using a twin-range method, with short-and long-range cutoffs of 0.8 and 1.4 nm, respectively. Neighbor searching was performed up to 1.4 nm and updated every two steps. A time step of integration of 2 fs was used. A reaction field correction for the electrostatic interactions was applied using a dielectric constant of 54. 25 The single-point charge model 26 was used for water molecules. The initial systems were energy minimized for 2000 steps using the steepest descent method, with all heavy atoms harmonically restrained using a force constant of 10 3 kJ mol
. The systems were initialized in the canonical ensemble (NVT) for 50 ps, with all heavy atoms harmonically restrained using a force constant of 10 3 kJ mol −1 nm −2 . The simulation was then continued for picoseconds in the isothermal−isobaric ensemble (NPT), with the heavy atoms harmonically restrained with the same force constant. Finally, to allow the equilibration of the system properties, the simulations were further extended in the NPT ensemble with position restraints applied to only the α-carbons. Pressure control was implemented using the Berendsen barostat, 27 with a reference pressure of 1 bar, a relaxation time of 0.5 ps, and an isothermal compressibility of 4.5 × 10 −5 bar −1
. Temperature control was set using the V-rescale 27, 28 thermostat at 300 K with coupling constants of 0.025 ps in the first two initialization steps and 0.1 ps for the rest of the simulations. At least three replica systems were simulated for each condition, from 50 ns using different initial velocities taken from a Maxwell−Boltzman distribution at 300 K. GROMACS tools were used to evaluate several properties of the systems, such as the pressure, temperature, and surface accessible solvent area, providing insights into the correct modeling of the protein−MTX interaction. In addition, pulling simulations were performed with FR−MTX and RFC−MTX conjugates, with a constant force of 1000 kJ mol −1 nm −2 and a rate of 0.1 nm/ns applied to the MTX molecule. The force applied in the MTX molecule obliges the molecule to exit from the active sites of the tested proteins. The MTX had its carboxyl group termination facing the solvent in both cases. Later an umbrella sampling methodology 29 was applied to calculate the potential of mean force for the process of MTX molecules exiting the FRα and RFC proteins.
■ RESULTS AND DISCUSSION
In this work, two fluorescently labeled conjugates of MTX, differently linked at the terminal groups (Figure 2 ), were considered for cellular uptake. Because high levels of FRα were reported in a wider spectrum of epithelial-origin tissues, 30 human epithelial adenocarcinoma cells of the mammary gland were selected for exposure to the antifolate conjugates, in comparison to a negative control. The FRα expression levels of the different-origin cancer cells were quantified using a standardized real-time qPCR detection system. The concentration of the conjugates internalized (adjusted for MTX concentration) was determined, considering the fluorescence measured in the lysates of the exposed cells. To ascertain the "targetability" of FRα, molecular docking simulations of the FRα−MTX complex were performed. This study adds information to the current understanding of the structural underpinnings of the transport of antifolatebased derivatives. Moreover, the interference of the chemical nature of their free terminal groups on the affinity and/or specificity of the molecular interactions involved in their cellular uptake was evaluated. The functional chemical groups of the MTX conjugates implicated in the binding to the surface-associated receptor, and their potential as a "tool" to surmount the membrane-spanning anion transporter, avoiding significant side effects and dose-limiting toxicities, are discussed.
Prior to cellular uptake experiments, FRα expression levels of the different-origin human cancer cells were confirmed. Real-time qPCR data analysis revealed higher expression levels of FRα in the KB cancer cell line and negligible levels in the MDA-MB-435S cell line ( Figure 3A) . 11 Although posttranscriptional regulation can occur, previous studies showed that the level of protein expression of FR 31, 32 and RFC 33, 34 in several cancer cell lines is directly proportional to mRNA levels.
The uptake concentration of the MTX conjugates, differently linked at the terminal functional groups, showed significant interaction among the selected factors. For FRα-positive cells, KB, significant statistical differences were observed among the internalized concentrations of the two MTX conjugates, whereas for the FRα-negative cells, MDA-MB-435S, negligible differences were observed ( Figure 3B ). Comparable amounts of both MTX conjugates, with either terminus blocked, were taken up similarly by FRα-negative cells. It is noteworthy that, although H 2 N-MTX-CO-FITC internalization remains unaltered after incubation with a high-affinity FR substrate (folic acid), 35 as expected, it is possible to observe an increase in the level of internalization after incubation with the high-affinity RFC substrate (calcium folinate). 36 Once RFC expression remains similar after incubation with the high-affinity RFC substrate ( Figure 3A) , one can speculate that another uptake mechanism is present or is activated in the presence of a huge quantity of the calcium folinate.
Higher concentrations of the H 2 N-MTX-CO-FITC conjugate were taken up by FRα-positive cells compared to that of the Red Mega-HN-MTX-COOH conjugate ( Figure 3B ). This result provides a proof of concept of higher passage of MTX via FRα when the amino groups are free. Furthermore, as expected, the level of internalization of the H 2 N-MTX-CO-FITC conjugate decreases after incubation with the high-affinity FR substrate, folic acid, remaining unaltered after incubation with the high-affinity RFC substrate, calcium folinate.
The receptors FRα and FRβ have high degrees of sequence identity (82%) and similarity (92%), with their binding sites being highly conserved, with only two divergent residues (V129α/F123β and K158α/R152β). 12 Although we did not perform studies with cell lines expressing FRβ, a behavior similar to that of FRα would be expected.
The ability of the conjugate with free amino groups to bind to FRα was further confirmed by molecular docking and molecular dynamics simulations, as shown in Figure 4 . Molecular docking experiments initially suggested that MTX is capable of binding to FRα using either the terminal amino group (Figure 4A ) or the terminal carboxylic group ( Figure 4B ). However, stabilization of these docking structures in water, using molecular dynamics simulation tools, showed that the complex is stable only if the amino groups are facing the FRα pocket and not the opposite.
Taking into account the molecular dynamics simulations, we calculated the binding energy between the two transport systems and MTX, using an umbrella sampling technique to calculate the potential of mean force. The final result demonstrates that the complex of MTX and RFC is stronger, with a binding energy of approximately 65 kcal mol −1 , comparatively ( Figure 5 ). In summary, the obtained outcomes provide a rationale for designing more specific drugs for selective approaches. Modulation of the MTX terminal groups might be a potentially useful strategy for improved mediated transport targeting through the FRα system on cancer cells (Figure 6 ). A major outcome anticipated from this study is the development of the next generation of FR-targeted therapeutics.
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